close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Encoded Therapeutics Inc.

News headline image
Encoded Therapeutics Presents Positive Interim Efficacy Data from Initial Dose Levels of Phase 1/2 Trials Evaluating ETX101 Gene Therapy in Dravet Syndrome
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics to Present Interim Phase 1/2 Clinical Data on ETX101, the First One-time Gene Therapy in Development for Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
New Preclinical Data from Encoded Therapeutics Demonstrate Therapeutic Potential of its One-time, Non-opioid Gene Therapy Candidate for Chronic Pain
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for ETX101 in SCN1A+ Dravet Syndrome
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics Presents Promising New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics to Present New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Demonstrates Therapeutic Potential of a Vectorized miRNA-based Approach for Angelman Syndrome at the FAST Annual Global Science Summit
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics Presents Preclinical Data Across its Gene Therapy Portfolio at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101
From Encoded Therapeutics Inc.
Via Business Wire
News headline image
Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101
From Encoded Therapeutics Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today